Development of Nanobodies as Theranostic Agents against CMY-2-Like Class C β-Lactamases.

Animals Rabbits Single-Domain Antibodies Precision Medicine beta-Lactamases / genetics beta-Lactamase Inhibitors Penicillins Antibodies Epitopes
CMY-2 β-lactamase antibiotic resistance class C beta-lactamase nanobodies new antibiotic scaffold paratopes structural biology

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
18 04 2023
Historique:
medline: 20 4 2023
pubmed: 10 3 2023
entrez: 9 3 2023
Statut: ppublish

Résumé

Three soluble single-domain fragments derived from the unique variable region of camelid heavy-chain antibodies (VHHs) against the CMY-2 β-lactamase behaved as inhibitors. The structure of the complex VHH cAb

Identifiants

DOI: 10.1128/aac.01499-22 PMID: 36892280 PMC: PMC10112224
pubmed: 36892280
doi: 10.1128/aac.01499-22
pmc: PMC10112224
doi:

Substances chimiques

Single-Domain Antibodies 0
beta-Lactamases EC 3.5.2.6
beta-Lactamase Inhibitors 0
Penicillins 0
Antibodies 0
Epitopes 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0149922

Références

Front Microbiol. 2016 Dec 23;7:2054
pubmed: 28066375
Nat Protoc. 2014 Mar;9(3):674-93
pubmed: 24577359
J Clin Microbiol. 2002 Jun;40(6):1947-57
pubmed: 12037047
J Clin Microbiol. 2005 Aug;43(8):4168-71
pubmed: 16081967
Nanomedicine. 2017 Feb;13(2):631-639
pubmed: 27520726
Antimicrob Agents Chemother. 2000 Feb;44(2):311-5
pubmed: 10639355
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1233-1239
pubmed: 32441172
Pharmaceuticals (Basel). 2012 Feb 16;5(2):209-35
pubmed: 24288089
PLoS One. 2015 Mar 24;10(3):e0120688
pubmed: 25803720
J Am Chem Soc. 2020 Aug 12;142(32):13756-13767
pubmed: 32686406
Int J Parasitol. 2019 Jul;49(8):635-645
pubmed: 31150611
Front Microbiol. 2021 Apr 01;12:626774
pubmed: 33868190
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877
pubmed: 31588918
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Clin Infect Dis. 2019 Sep 27;69(8):1446-1455
pubmed: 30838380
J Antimicrob Chemother. 2010 Oct;65(10):2089-96
pubmed: 20801781
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
J Immunoassay Immunochem. 2016;37(1):80-9
pubmed: 26023821
Mol Immunol. 2003 Sep;40(1):25-33
pubmed: 12909128
Talanta. 2016 Jan 15;147:523-30
pubmed: 26592642
BMC Genomics. 2018 Aug 9;19(1):601
pubmed: 30092762
Clin Microbiol Rev. 2018 Feb 14;31(2):
pubmed: 29444952
Pathology. 2015 Jun;47(4):386-8
pubmed: 25938360
J Clin Microbiol. 2002 Jun;40(6):2153-62
pubmed: 12037080
Antimicrob Agents Chemother. 2001 Dec;45(12):3279-86
pubmed: 11709298
Proc Natl Acad Sci U S A. 1965 Oct;54(4):1133-41
pubmed: 5219821
Clin Infect Dis. 2019 Jan 18;68(3):519-524
pubmed: 30020449
J Med Microbiol. 2019 Mar;68(3):379-381
pubmed: 30663953
ILAR J. 2005;46(3):258-68
pubmed: 15953833
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Science. 2019 May 24;364(6442):
pubmed: 31123109
Nat Struct Biol. 2002 Nov;9(11):870-6
pubmed: 12389036
Annu Rev Biochem. 2013;82:775-97
pubmed: 23495938
Antimicrob Agents Chemother. 2005 Oct;49(10):4240-6
pubmed: 16189104
Microb Drug Resist. 2019 Jul/Aug;25(6):890-908
pubmed: 30811275
Chemistry. 2017 Jul 18;23(40):9632-9640
pubmed: 28449310
Cell Mol Life Sci. 2002 Jul;59(7):1223-32
pubmed: 12222968
J Immunol. 1999 Mar 15;162(6):3663-71
pubmed: 10092828
Biochem J. 2013 Mar 15;450(3):477-86
pubmed: 23289540
Anal Chim Acta. 2018 Oct 31;1029:65-71
pubmed: 29907292
Structure. 2002 Mar;10(3):413-24
pubmed: 12005439
Antimicrob Agents Chemother. 2015 Oct 05;60(1):6-13
pubmed: 26438495
Chem Rev. 2005 Feb;105(2):395-424
pubmed: 15700950
PLoS One. 2011 Apr 01;6(4):e17665
pubmed: 21483777
Microb Drug Resist. 2021 Nov;27(11):1578-1584
pubmed: 33913753
Antimicrob Agents Chemother. 2001 Oct;45(10):2807-12
pubmed: 11557473
Theranostics. 2015 Aug 01;5(10):1154-65
pubmed: 26284145
Antibodies (Basel). 2022 Jan 13;11(1):
pubmed: 35076451
Cold Spring Harb Perspect Med. 2016 Aug 01;6(8):
pubmed: 27329032
FEMS Microbiol Rev. 2012 Mar;36(2):340-63
pubmed: 21707670
J Infect Dis. 2011 Apr 15;203(8):1063-72
pubmed: 21450996

Auteurs

Frédéric Cawez (F)

InBioS, Center for Protein Engineering, Biological Macromolecules, Department of Life Sciences, University of Liège, Liège, Belgium.

Paola Sandra Mercuri (PS)

InBioS, Center for Protein Engineering, Biological Macromolecules, Department of Life Sciences, University of Liège, Liège, Belgium.

Francisco Javier Morales-Yãnez (FJ)

InBioS, Center for Protein Engineering, NEPTUNS, Department of Life Sciences, University of Liège, Liège, Belgium.
ALPANANO, Center for Protein Engineering & FARAH, University of Liège, Liège, Belgium.

Rita Maalouf (R)

InBioS, Center for Protein Engineering, NEPTUNS, Department of Life Sciences, University of Liège, Liège, Belgium.

Marylène Vandevenne (M)

InBios, Center for Protein Engineering, ROBOTEIN, Department of Life Sciences, University of Liège, Liège, Belgium.

Frederic Kerff (F)

InBioS, Center for Protein Engineering, Department of Life Sciences, University of Liège, Liège, Belgium.

Virginie Guérin (V)

Bacteriology, FARAH and Faculty of Veterinary Medicine, Department of Infectious and Parasitic Diseases, University of Liège, Liège, Belgium.

Jacques Mainil (J)

Bacteriology, FARAH and Faculty of Veterinary Medicine, Department of Infectious and Parasitic Diseases, University of Liège, Liège, Belgium.
ORCID: 0000-0001-8520-0834

Damien Thiry (D)

Bacteriology, FARAH and Faculty of Veterinary Medicine, Department of Infectious and Parasitic Diseases, University of Liège, Liège, Belgium.
ORCID: 0000-0002-5161-7364

Marc Saulmont (M)

Regional Animal Health and Identification Association (ARSIA), Ciney, Belgium.

Alain Vanderplasschen (A)

ALPANANO, Center for Protein Engineering & FARAH, University of Liège, Liège, Belgium.
Immunology-Vaccinology, FARAH and Faculty of Veterinary Medicine, Department of Infectious and Parasitic Diseases, University of Liège, Liège, Belgium.

Pierre Lafaye (P)

Institut Pasteur, Université Paris Cité, CNRS UMR 328, Paris, France.

Gabriel Aymé (G)

Institut Pasteur, Université Paris Cité, CNRS UMR 328, Paris, France.

Pierre Bogaerts (P)

National Reference Center for Antibiotic-Resistant Gram-Negative Bacilli, Department of Clinical Microbiology, CHU UCL Namur, Yvoir, Belgium.
ORCID: 0000-0002-4016-3707

Mireille Dumoulin (M)

InBioS, Center for Protein Engineering, NEPTUNS, Department of Life Sciences, University of Liège, Liège, Belgium.
ALPANANO, Center for Protein Engineering & FARAH, University of Liège, Liège, Belgium.

Moreno Galleni (M)

InBioS, Center for Protein Engineering, Biological Macromolecules, Department of Life Sciences, University of Liège, Liège, Belgium.
ORCID: 0000-0003-0992-0391

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Development of Nanobodies as Theranostic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Lagomorpha › Lapins › Development of Nanobodies as Theranostic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Fragments d'immunoglobuline › Fragments Fab d'immunoglobuline › Anticorps à domaine unique › Development of Nanobodies as Theranostic...
questionsmedicales.fr › Professions de santé › Médecine › Médecine clinique › Médecine de précision › Development of Nanobodies as Theranostic...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Amidohydrolases › bêta-Lactamases › Development of Nanobodies as Theranostic...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Inhibiteurs des bêta-lactamases › Development of Nanobodies as Theranostic...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Pénicillines › Development of Nanobodies as Theranostic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Development of Nanobodies as Theranostic...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Épitopes › Development of Nanobodies as Theranostic...